New antibody shows promise against rare liver infection
NCT ID NCT05861674
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called HH-003 in 101 adults with chronic hepatitis delta, a serious liver disease. HH-003 is an antibody that targets hepatitis B virus, which is needed for hepatitis delta to survive. Participants received either a low or high dose of HH-003 plus standard care, or standard care alone, for 48 weeks. The goal was to see if the drug could lower virus levels and improve liver health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HH-003 (a monoclonal antibody targeting hepatitis B virus)
- What this could lead to
- If successful, this could point toward a new treatment option for chronic hepatitis delta, a serious liver disease with few approved therapies.
- What could go wrong
- This is a mid-stage trial with only 101 participants, so results may not confirm effectiveness or safety. The treatment targets hepatitis B, but the disease is caused by hepatitis delta, so it may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS DELTA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Ditan Hospital Captial Medical University
Beijing, Beijing Municipality, 100015, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.